LBRX
LB Pharmaceuticals Inc Common Stock
$23.86
2.69
(12.71%)
| Exchange: | |
| Market Cap: | 603.637M |
| Shares Outstanding: | 3.541M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Heather D. Turner | |||||
| Full Time Employees: | 16 | |||||
| Address: |
|
|||||
| Website: | https://lbpharma.us |
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
Could not create stock discussion for LBRX
